4547:TYO
Kissei Pharmaceutical Co Ltd
Â¥3,885.00
arrow_upward
+1.44%(+55.00) 1D
Nov 13, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
Â¥3,860
High
Â¥3,885
Low
Â¥3,830
Mkt. cap
180.82B
Avg. vol.
85.82K
Volume
77.00K
Dividend
3.22%
Quarterly dividend
Â¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
14.40
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
Open
Â¥3,860
High
Â¥3,885
Low
Â¥3,830
Mkt. cap
180.82B
Avg. vol.
85.82K
Volume
77.00K
Dividend
3.22%
Quarterly dividend
Â¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
14.40
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
The Motley Fool
·
16 minutes ago
Prediction: This Small-Cap Value ETF Will Beat the S&P 500 Over the Next 10 Years
Bloomberg.com
·
1 hour ago
SpaceX’s S&P 500 Bid Gets New Life as Musk Pitches Tesla Merger
Trefis
·
8 hours ago
S&P 500 Movers | Winners: CHTR, STE, GPN | Losers: AMD, DELL, CSCO
Traders Union
·
3 hours ago
Gold volatility surpasses S&P 500 by 2.1 times, Mike McGlone notes
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp